Atlas Trials

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

Clinical trial NCT01853982 · TERMINATED

Trial details

NCT number
NCT01853982
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Ventilator-Associated Pneumonia (VAP)
Start date
2013-06-14
Primary completion
2013-11-20
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.